Kalvista Pharmaceuticals Inc (KALV) Stock
KALV is no longer traded. Kalvista Pharmaceuticals was acquired by Chiesi in June 2026.
Each KALV share was exchanged for $27.00 in cash. Prices on this page are historical; the last trade was June 10, 2026 at $27.00.
Kalvista Pharmaceuticals stock price history
KALV final trading statistics
- Final close
- $27.00
- Final trading day
- Jun 10, 2026
- Market cap at delisting
- $1.44B
- Shares outstanding
- 53.24M
- Final 52-week range
- $9.83 – $27.00
- Avg. volume (final 3 mo.)
- 3,482,076
- All-time high (split-adj.)
- $126.56 · Jun 2015
- All-time low (split-adj.)
- $4.20 · Oct 2022
- Return since IPO
- -65.3%
- Beta
- -0.11
- Book value / share
- -$0.38
- Price / book
- -70.31
Kalvista Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2026 | $73.62M | -$164.3M | -$1.53 |
| FY2025 | $0.00 | -$183.4M | -$3.69 |
| FY2024 | $0.00 | -$126.6M | -$3.40 |
| FY2023 | $0.00 | -$92.9M | -$3.36 |
| FY2022 | $0.00 | -$82.3M | -$3.36 |
Last five fiscal years reported before the delisting; fiscal year ending April. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kalvista Pharmaceuticals Inc
As of June 11, 2026, KalVista Pharmaceuticals, Inc. was taken private. KalVista Pharmaceuticals, Inc. operates as a biopharmaceutical company that develops oral therapies for rare diseases in worldwide markets. It offers sebetralstat, a novel, oral, on-demand treatment for hereditary angioedema (HAE), and an oral Factor XIIa inhibitor program. KalVista Pharmaceuticals, Inc. was formerly known as KalVista Pharmaceuticals Ltd. and changed its name to KalVista Pharmaceuticals, Inc. in November 2016. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts. As of June 11, 2026, KalVista Pharmaceuticals, Inc. operates as a subsidiary of Chiesi Farmaceutici S.p.A.
Kalvista Pharmaceuticals stock FAQ
What happened to Kalvista Pharmaceuticals stock?
Kalvista Pharmaceuticals was acquired by Chiesi in June 2026. Shareholders received $27.00 in cash for each share. KALV stock stopped trading on the Nasdaq, with a final close of $27.00 on June 10, 2026.
What did Kalvista Pharmaceuticals shareholders receive?
Each KALV share was converted into $27.00 in cash. The deal was valued at about $1.64 billion.
Is KALV stock still trading?
No. KALV was delisted from the Nasdaq in June 2026 and no longer trades on a U.S. exchange.
What was the last price of KALV stock?
KALV closed at $27.00 on its final trading day, June 10, 2026, for a market value of about $1.44B.
What were Kalvista Pharmaceuticals's revenue and earnings in its last full fiscal year?
Kalvista Pharmaceuticals reported revenue of $73.62M and net income of -$164.3M in fiscal 2026, its last full year as a public company.
When did Kalvista Pharmaceuticals go public?
Kalvista Pharmaceuticals Inc stock began trading on April 9, 2015.